Access Pharmaceuticals Provides Update on ProLindac(TM) Phase 2 Ovarian Cancer Trial and Clinical Development Plan
...eria . No patient in any dose group exhibited any signs of acute neurotoxicity, which is a major adverse side-effect of the approved DACH platinum, eloxatin
, and ProLindac was well tolerated overall. The Company has scaled up manufacturing in order to begin the next phase of clinical development. Access ...
Sanofi-aventis Announces Good First-quarter 2009 Performance
...cation approved in the second half of 2008. In the United States, the product posted 2.9% growth in net sales to euro 197 million.
Net sales of eloxatin
(R) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as first line treatment in the metastatic phase, were up 3.0% at...
Sanofi-aventis Delivers 2008 Results Above Guidance
...sed by 17.8% (to EUR 49 million) in the fourth quarter and by 14.9% (to EUR 142 million) over the full year.
In the United States, net sales of eloxatin
(R) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and in the metastatic phase, rose by 6.9% to EUR 265 million in the ...
Eloxatin combination reduces bowel cancer recurrences
...study involving patients taking supplementation of eloxatin
drug with other chemotherapeutic cancer drug for t...s called as NICE study has proved a combination of eloxatin
with chemotherapeutic drugs more effective than co...nic acid.
The study has found combination of eloxatin
with 5-Fluorouracil and Folinic acid more effectiv...
Eloxatin in Medical Technology
Eloxatin in Medical Dictionary
...se. Read more about the prescription drug OXALIPLATIN - INJECTION . ... home > oxaliplatin- injection index > oxaliplatin- injection , eloxatin
drug monograph ... Consumer information about the medication FOLIC ACID - INJECTION (Folvite), includes side effects, drug interactions, rec...
Eloxatin in Biological Technology
The Foundation for National Institutes of Health Announces Unprecedented Product Donation by sanofi-aventis in the U.S.
...in New York (NYSE: SNY ). For more information, visit: www.sanofi-aventis.us or www.sanofi-aventis.com .
Please see the accompanying eloxatin
(oxaliplatin injection), Lovenox (enoxaparin sodium injection), and Taxotere (docetaxel) Injection Concentrate full prescribing information, including...
Sanofi-aventis Announces Second Quarter 2009 Results
...h metastatic breast cancer, based on the results of the AVADO study. First-half net sales of Taxotere((R)) were up 9.5% at euro 1,118 million.
((R)) , the leading cytotoxic agent in the colorectal cancer market as an adjuvant and as a first-line treatment in the metastatic phase, achieved se...
Hospira Receives Favorable Court Decision on Eloxatin(R)
...e generic name oxaliplatin injection, will be one of the first generic versions available in the United States to come in solution form. U.S. sales of eloxatin
last year were approximately $1.4 billion.
"We are extremely pleased with the court's ruling," said Joshua Gordon, vice president, Specialty Phar...
Poniard Pharmaceuticals Announces Positive Tumor Response and Neuropathy Data from Phase 2 Clinical Trial of Picoplatin in Metastatic Colorectal Cancer
...). Results also continue to indicate that both regimens have similar anti-tumor activity in first-line metastatic CRC. Net sales in 2007 in the US for eloxatin
(oxaliplatin) were approximately $1.3 billion.
"These new data continue to suggest that picoplatin is an active platinum agent in colorectal canc...
Barr Confirms Patent Challenge of Eloxatin(R) Injectable, 5mg/mL
...ug Application (ANDA) containing a
paragraph IV certification for a generic eloxatin
product with the U.S.
Food & Drug Administration (FDA), and following FDA n...rmally initiates the patent challenge process under
the Hatch-Waxman Act.
(Oxaliplatin Aqueous Solution), 5mg/mL Injectable, used in
Access Highlighted in Recent BusinessWeek Article
...rcial also noted that Dr. Esteban Cvitkovic, Access' Vice-Chairman
(Europe) and Senior Director, Oncology Clinical R&D, was responsible for
during his tenure at Sanofi-Aventis. The article
references certain products of Somanta Pharmaceuticals in the cancer area.
While Access has executed ...